BRII 778
Alternative Names: BRII-778Latest Information Update: 29 Dec 2022
At a glance
- Originator Brii Biosciences
- Class Antiretrovirals; Antivirals
- Mechanism of Action HIV replication inhibitors; HIV reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Dec 2022 Discontinued - Phase-I for HIV infections in USA based on phase I pharmacokinetic data (PO)
- 19 Oct 2022 Pharmacokinetics data from a phase I trial in HIV infections presented at the IDWeek 2022(IDW-2022)
- 19 Oct 2022 Pharmacokinetic and adverse events data from a phase I trial in HIV infections released by Brii Biosciences